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Target profiling of zerumbone using a novel cell-
permeable clickable probe and quantitative chemical 
proteomics  
Karunakaran A. Kalesh,a James A. Clulow a and Edward W. Tatea*  
 
 
 
 
Zerumbone is a phytochemical with diverse biological 
activities ranging from anti-inflammatory to anti-cancer 
properties; however, to date the cellular targets of this 
important compound have remained elusive. Here we report 
the global protein target spectrum of zerumbone in living 
cancer cells using competitive activity-based protein profiling 
of a novel cell-permeable clickable probe, combined with 
quantitative mass spectrometry. 
Zerumbone, (2,6,9,9-tetramethyl-[2E,6E,10E]-cycloundeca-2,6,10-
trien-1-one), is a cyclic sesquiterpene isolated from the tropical plant 
Zingiber zerumbet Smith. Many in vitro and in vivo studies have 
indicated anti-cancer, anti-inflammatory and cellular detoxification 
properties for the compound,1 however, the protein targets that may 
underlie these activities are yet to be characterised. The unusual 
cyclic α,β-unsaturated ketone functionality in the molecule (Fig. 1a) 
has been found to be essential for activity as it provides electrophilic 
Michael addition centres for irreversible covalent binding of target 
proteins via nucleophilic residues.2 Zerumbone-bound sepharose gel 
and a biotinylated zerumbone derivative have been reported as 
biochemical tools for target profiling of this important bioactive 
compound,3 but are of limited use in determining targets in living 
cells since these probe designs preclude representative cell-based 
experiments. We therefore designed a cell-permeable clickable probe 
and report herein the application of this probe in intact cells 
revealing, for the first time, the broad target spectrum of zerumbone 
using quantitative mass spectrometry-based chemical proteomics. 
Clickable small-molecule probes have been instrumental in target 
and off-target profiling of many drugs and biologically active natural 
products.4 In order to elucidate the target spectrum of zerumbone we 
designed and synthesised the terminal alkyne incorporated 
zerumbone derivative Yn-Zer (Fig. 1a and ESI† Scheme 1) that 
places the tag distal to the key reactive centres in Zer (Fig. 1b). 
 
Fig. 1 (a) Structures of zerumbone (Zer), probe (Yn-Zer) and inactive 
zerumbone derivative α-humulene. (b) A potential mechanism of 
addition between nucleophilic target protein residues (Nu) and Yn-Zer. 
c) Competitive profiling against Yn-Zer in cells leads to targets of Zer. 
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Fig. 2 In-gel fluorescence imaging of Yn-Zer-labelled HeLa proteome. 
(a) Lysate based labelling. (b) Intact cell-based labelling.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The probe design includes an α,β-unsaturated amide that is relatively 
much less reactive than ketone-conjugated alkenes such as those 
required for activity in Zer. We anticipated that any interference in 
target profiling would be factored out during quantitative analyses in 
cells (Fig. 1c), which depend on competition of Zer against Yn-Zer, 
rather than on identification of the probe targets themselves. Initial 
gel-based labelling experiments were carried out using HeLa whole 
cell lysates. The probe-treated lysate was subjected to copper 
catalysed azide-alkyne cycloaddition reaction (CuAAC) using a 
trifunctional capture reagent azido-TAMRA-biotin (AzTB) 
previously developed in our lab (see ESI†).5 Proteome labelling was 
evaluated by in-gel fluorescence scanning following SDS-PAGE 
(Fig.2a). Multiple protein bands were labelled by the probe, and 
these were readily outcompeted with excess zerumbone. However, 
competition against α-humulene, a zerumbone derivative that lacks 
the reactive ketone functionality (Fig. 1a), showed no effect on 
labelling efficiency. This underlines the importance of the α,β-
unsaturated ketone functionality in the protein reactivity of the probe 
and the parent compound, and suggests that the unsaturated amide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 (a) Overview of ‘spike-in’-SILAC-coupled quantitative chemical proteomics methodology. (b) Key biological processes affected by 
zerumbone treatment revealed by DAVID bioinformatic analysis of 151 zerumbone-competed protein IDs. (c) Log2 fold change in the H/L ratios 
of identified hits upon zerumbone treatment vs. no zerumbone treatment as a function of statistical significance (-Log ANOVA p value) across 
the three biological replicates. The variance tested was the variance of means of H/L ratios of each protein across the three biological replicates. 
Top targets identified at 75µM and 100µM zerumbone are labelled (gene names) on the plot.   
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Table 1 Top 20 targets of zerumbone revealed in this study. 
in Yn-Zer does not significantly influence labelling. 
We next investigated intact cell-based labelling using Yn-Zer. HeLa 
cells gown in DMEM medium pre-incubated with zerumbone or α-
humulene (or DMSO as a vehicle control) for 30 min were treated 
with Yn-Zer. The cells were then washed with PBS, lysed and the 
lysates subjected to CuAAC ligation to AzTB followed by protein 
resolution on SDS-PAGE and in-gel fluorescence scanning (Fig. 2b). 
Labelling of several cellular proteins was observed and as in the case 
of the lysate-based experiment only the parent compound 
outcompeted proteome labelling by the probe, with α-humulene 
displaying no detectable effect. A comparison of the lysate- and cell-
based experiments revealed significantly different labelling patterns, 
highlighting the importance of intact cell-based labelling for 
validation of physiologically relevant targets, which is a particular 
advantage of the current probe design. 
Encouraged by the results from gel-based labelling, we performed 
large-scale proteomic experiments using a combination of probe 
labelling and Stable Isotope Labelling by Amino acids in Cell 
culture (SILAC)-based quantitative mass spectrometry (MS).6 A 
‘spike-in’ SILAC approach7 (Fig. 3a), as recently implemented for 
human N-myristoyltransferase (NMT) substrate discovery,8 was 
envisaged for global profiling of zerumbone targets as this method 
enables an unbiased, high-confidence approach to target 
identification directly in the native cellular environment (i.e. at 
endogenous expression level and native protein folding). Spike-in 
SILAC methodology normalises all experimental samples across all 
sample handling steps and since heavy isotope labelling is required 
only for the ‘spike-in’-standard, the experimental samples and the 
system under investigation are free from any potential disruption 
from isotope labelling or use of particular media. Briefly, HeLa cells 
cultured in normal DMEM media were treated separately in 
triplicate with 20µM Yn-Zer alone or with 20µM Yn-Zer in 
combination with three different concentrations (75, 100 and 150µM 
respectively) of zerumbone. In parallel, HeLa cells labelled with 
15N413C6-arginine and 15N213C6-lysine (R10K8 HeLa cells) cultured 
and maintained in R10K8 DMEM media were treated with 20µM 
Yn-Zer to generate the ‘spike-in’ SILAC standard. After compound 
incubation cells were lysed, and lysate protein concentrations 
normalised across all samples. Heavy lysates were spiked into each 
sample in a 1:1 ratio, and the mixture subjected to CuAAC reaction 
with AzTB, as described above. The samples, after protein 
precipitation to remove capture reagent excess, were re-dissolved in 
protein buffer and subjected to affinity purification on NeutrAvidin-
Agarose resin, followed by nanoLC-MS/MS proteomic analysis and 
data processing as described in the ESI. 
A stringent cut-off threshold of at least 6 valid quantifications across 
the 12 samples for each protein led to identification of >600 proteins 
(ESI Supporting Table 1). Of these identified hits, 151 proteins 
displayed concentration-dependent competition against the parent 
compound (blue in ESI Supporting Table 1), suggesting that they are 
genuine cellular targets of the phytochemical. The high 
reproducibility of the data is clearly evident from the scatter plots 
displaying nearly linear relationship (ESI† Fig. S3) between H/L 
ratios of the majority of identified protein targets across the three 
biological replicates of each tested concentration of the parent 
compound. Multiple unique peptides (often 7 or more at a stringent 
false discovery rate of <1%) were identified for each protein target 
across the proteomic samples, along with high protein sequence and 
unique sequence coverage (ESI Supporting Table 1). The capability 
to assign rigorous and robust identity and quantification from 
multiple unique peptide data points during competition experiments 
highlights the advantages of MS/MS-based quantitative chemical 
proteomics in complex systems. Furthermore, the competition-based 
‘spike-in’ SILAC methodology factors out any interference that 
might result from the conjugated amide in Yn-Zer. 
Bioinformatic analysis of the zerumbone-competed proteome (151 
protein IDs)  using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) bioinformatics resource9 revealed 
several specific key biological processes (Fig. 3b, ESI† Supporting 
Table 4) and biological pathways (ESI† Fig S1 & Supporting Table 
3) that are targeted by zerumbone. In order to identify the most 
significantly engaged targets we plotted Analysis of Variance 
(ANOVA) significance (-log ANOVA p values) of all identified 
proteins as a function of fold change in enrichment following 
zerumbone treatment. As shown in Fig. 3a, proteins that are heavily 
enriched and significant will fall in the upper right quadrant and are 
high-confidence targets, whilst those in the lower right quadrant are 
also enriched but lack strong statistical significance, and thus 
represent lower-confidence targets. Proteins in the upper left 
quadrant, although statistically significant, are not strongly enriched, 
and those in the lower left quadrant are likely non-specific binders 
that are neither strongly enriched nor statistically significant. As 
shown in Fig. 3c, a total of 20 proteins (blue filled circles) displayed 
statistically significant enrichment at 75µM zerumbone, and with 
increasing concentration of competing zerumbone more protein 
targets are identified (7 additional targets at 100µM zerumbone and 
gene symbol localisation major protein functions 
DFNA5 
 
cytoplasm apoptosis, cancer and cell survival. 
CDA cytoplasm, 
nucleus 
scavenges cytidine and 2'-deoxycytidine for UMP synthesis 
 
 
UVRAG endosome, 
lysosome 
DNA repair, positive regulation of autophagy, regulation of 
intrinsic pathway of apoptosis 
 
LCMT1 cytoplasm c-terminal protein methylation, regulation of apoptosis 
 
NT5DC1 cytosol hydrolase 
 
CPPED1 cytoplasm protein phosphatase of Akt-family kinases, blocks cell 
cycle progression and promotes apoptosis 
 
NT5CD2 mitochondrion hydrolase 
 
FAM114A1 cytoplasm neuronal cell development 
 
GCLC cytoplasm, 
cytosol 
glutathione biosynthesis, cell redox homeostasis, apoptotic 
mitochondrial changes 
 
MLKL cell membrane, 
cytoplasm 
 
TNF-induced necroptosis  
NR3C1 cytoplasm, 
mitochondrion, 
nucleus 
 
transcription regulation, affects inflammatory responses 
and cellular proliferation  
ATXN10 cytoplasm necessary for the survival of cerebellar neurons, apoptosis  
 
TMPO nucleus regulation of transcription 
 
RPS6KA1 nucleus, 
cytoplasm 
 
serine/threonine kinase that regulate many cellular 
processes including growth, motility, survival and 
proliferation.  
 
BRAT1 nucleus cellular response to DNA damage  
 
MCMBP nucleus cell cycle, cell division, DNA replication, mitosis 
 
MAGED2 cytosol, 
nucleus 
tumor antigen, protects melanoma cells from apoptosis 
induced by TRAIL 
 
UQCRC1 mitochondrion electron transport 
 
SYNCRIP cytoplasm, ER, 
microsome, 
nucleus, 
spliceosome 
 
translation regulation, mRNA processing and splicing, 
host-virus interaction 
DUT mitochondrion, 
nucleus 
nucleotide metabolism 
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35 additional targets at 150µM zerumbone). Table 1 lists the top 20 
targets and their key biological functions (ESI† Supporting Table 2 
lists the complete list of high-confidence targets and their key 
biological functions). The top targets of zerumbone are involved in 
vital biological processes, with many playing key roles in regulating 
apoptosis and cell survival. This multi-target activity of zerumbone 
demonstrated in this study strongly suggests that the compound 
exerts its biological effects via modulation of a variety of these 
targets in an interactome co-dependent and context-dependent 
manner.  
Conclusions 
In conclusion, we report the first large-scale profiling of 
zerumbone targets directly in live cancer cells using an 
integrated chemical proteomic approach that combines a cell-
permeable small-molecule chemical probe with ‘spike-in’ 
SILAC-based quantitative proteomics. Using this methodology, 
the most potently engaged targets of the phytochemical could 
be determined in a concentration-dependent and high-
throughput manner, in a native cellular environment. The data 
presented here provides valuable insights into molecular targets 
that potentially lead to the phenotypic changes and 
physiological effects observed following in vitro and in vivo 
administration of the phytochemical, and provide a basis for 
future biochemical studies to establish the mode of action of 
zerumbone. It is also important to note that many of the 
identified targets are implicated in diseases including cancers. 
Selective and potent inhibitors are not yet available for most of 
these targets, and this study could provide a starting point for 
inhibitor scaffolds against these proteins. Finally, as many 
biologically active natural products elicit their effects through 
multiple cellular targets rather than one single target, there may 
be physiologically and pathologically relevant co-dependencies 
across the identified targets and their interactome networks. For 
any given natural product, this network will require further 
investigation in order to reveal the complete molecular 
mechanisms behind their biological effects. Investigations in 
this direction for zerumbone are in progress in our group, and 
the results will be reported in due course.  
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